tbuckley/cabot-search huggingface dataset:
AB0152 Disease activity and damage scores correlated differently with the patient reported outcomes in patients with primary SJÖGREN'S syndrome compared to lupus associated with secondary SJÖGREN'S syndrome
Authors: N Thompson, V Gupta, A Gandhi, R Radmore, S Cho, DA Isenberg, EC Jury, C Ciurtin
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Previous studies showed a poor correlation between EULAR Sjögren9s Syndrome Patient Reported Index (ESSPRI) and EULAR Sjögren9s Syndrome Disease Activity Index (ESSDAI) in patients with Sjögren9s syndrome (SS) (1). There are no previous studies correlating these scores with the SS Disease Damage Index (SSDDI) or assessing comparatively patients with primary (pSS) and secondary SS associated with lupus (SLE/SS). <h3>Objectives</h3> We aimed to assess how well scores assessing disease activity, damage and patient reported outcomes correlate with each other in patients with pSS compared to SLE/SS. <h3>Methods</h3> We conducted a cross-sectional study of 55 patients with pSS and 15 SLE/SS. Detailed clinical and laboratory data, along with patient reported outcomes (ESSPRI) and disease activity and damage scores (ESSDAI, BILAG and SSDDI) were collected. We compared the clinical and laboratory parameters of the two patient groups (pSS and SLE/SS) and assessed the correlations between maximum ESSDAI score since diagnosis and ESSDAI, ESSPRI, SSDDI and BILAG scores at the time of assessment. <h3>Results</h3> The table below shows comparatively the differences between the pSS and SLE/SS patient groups. We found significant correlations of SSDDI score with disease duration and maximum ESSDAI score in patients with pSS (r=0.27, p=0.05 and r=0.67, p=0.0001, respectively). In SLE/SS patients, ESSPRI scores correlated with both BILAG and maximum ESSDAI score (r=0.55, p=0.03 and r=0.7, p=0.02, respectively). The SSDDI score correlated with the disease duration only in pSS patients (r=0.27, p=0.05). <h3>Conclusions</h3> Our study showed that there was no similar correlation between various disease scores in patients with pSS compared to SLE/SS patients. If the patient reported outcomes correlated with the disease activity (ESSDAI and BILAG) in SLE/SS patients, this correlation was not seen in pSS patients, in which the significant correlations were found only between damage scores, highest disease activity score and disease duration. <h3>References</h3> Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren9s syndrome treated with rituximab, Ann Rheum Dis 2012;71:. <h3>Disclosure of Interest</h3> None declared
A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study)
Authors: Takashi Kobayashi, Yasuhito Nannya, Motoshi Ichikawa, Kenji Oritani, Yuzuru Kanakura, Akihiro Tomita, Hitoshi Kiyoi, Masayoshi Kobune, Junji Kato, Hiroshi Kawabata, Motohiro Shindo, Yoshihiro Torimoto, Yuji Yonemura, Nobuyoshi Hanaoka, Hideki Nakakuma, Daisuke Hasegawa, Atsushi Manabe, Naohito Fujishima, Nobuharu Fujii, Mitsune Tanimoto, Yasuyoshi Morita, Akira Matsuda, Atsushi Fujieda, Naoyuki Katayama, Haruhiko Ohashi, Hirokazu Nagai, Yoshiki Terada, Masayuki Hino, Ken Sato, Naoshi Obara, Shigeru Chiba, Kensuke Usuki, Masatsugu Ohta, Osamu Imataki, Makiko Uemura, Tomoiku Takaku, Norio Komatsu, Akira Kitanaka, Kazuya Shimoda, Kenichiro Watanabe, Kaoru Tohyama, Akifumi Takaori‐Kondo, Hideo Harigae, Shunya Arai, Yasushi Miyazaki, Keiya Ozawa, Mineo Kurokawa
Journal: American Journal of Hematology (2017)

Hypoplastic myelodysplastic syndrome (hMDS) is a distinct entity with bone marrow (BM) hypocellularity and the risk of death from BM failure (BMF). To elucidate the characteristics of hMDS, the data of 129 patients diagnosed between April 2003 and March 2012 were collected from 20 institutions and the central review team of the National Research Group on Idiopathic Bone Marrow Failure Syndromes, and compared with 115 non-hMDS patients. More RA and fewer CMMoL and RAEB-t in French-American-British (FAB) and more RCUD and MDS-U and fewer RCMD in World Health Organization (WHO) classifications were found in hMDS than non-hMDS with significant differences. The overall survival (OS) and AML progression-free survival (AML-PFS) of hMDS were higher than those of non-hMDS, especially in patients at age ≥50 and of lower risk in Revised International Prognostic Scoring System (IPSS-R). In competing risks analysis, hMDS exhibited decreased risk of AML-progression in lower IPSS or IPSS-R risk patients, and higher risk of death from BMF in patients at age ≥50. Poor performance status (PS ≥2) and high karyotype risks in IPSS-R (high and very high) were significant risk factors of death and AML-progression in Cox proportional hazards analysis.
SP0041 Current needs for rehabilitation
Authors: M Björk
Journal: Annals of the Rheumatic Diseases (2017)

New biological medications and earlier multi professional interventions have led to a reduction in the extent of disability for patients with rheumatic diseases. However disability still remains a key problem for many patients and patients may experience participation restrictions even though they are achieving "remission". To be able to engage in the things we want or need to do is crucial to our health and sometimes a challenge to meet for health professionals. Also, there is an on going discussion of whether today9s patients have new rehabilitation needs and if they are met by the health care. This session summarizes both qualitative and quantitative evidence of the disability in today9s patients with arthritis. It will further discuss the current needs of rehabilitation in today9s patient in relation to existing standards and guidelines. Rehabilitation interventions and patient reported strategies in relation to pain, fatigue and affected activity balance will be highlighted since they are common disabilities among today9s patients. <h3>Disclosure of Interest</h3> None declared
AB1152 The incidence of hypersensitivity to nsaids in the group of patients with musculoskeletal disorders
Authors: O Brzezińska-Pawłowska, A Sztanka, K Słodkowski, A Lewandowska-Polak, J Makowska
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most common cause of drug hypersensitivity reactions (DHR). Recent studies show that the prevalence of hypersensitivity reaction to drug is particularly in Poland. <h3>Objectives</h3> To assess the frequency and the risk od developing NSAID hypersensitivity in patients with chronic disorders of the musculoskeletal system. <h3>Methods</h3> The study group consisted of 200 patients (age 19–88 years - 54,5±14, women-161, men-39) hospitalized in the Department of Rheumatology in 2015–2016. All patients filled questionnaire regarding symptoms of DHR after ingestion of non-steroidal anti-inflammatory drugs. The presence of DHR, clinical pattern of the reaction, frequency of NSAIDs administration and comorbidities have been studied. In statistical studies the main risk factors were defined. <h3>Results</h3> Seventy-seven patients from study group (38,5%) reported symptoms that occurred within 24 hours after NSAIDs ingestion. Symptoms characteristic for hypersensitivity reaction were reported by 40 patients (20%). Respiratory symptoms like dyspnea and/or cough were reported by 22 patients (11%). Cutaneous symptoms (urticaria/angioedema/dermal flush) were reported also by 29 patients (14,5%). Three patients experienced loss of consciousness. Thirty-seven patients reported isolated stomach cramps. The symptoms developed usually between 2–12 hours after drug intake. In 37 patients oral administration caused DHR reaction, moreover in 14 patients also topical application led to adverse reaction. In most of patients reaction appeared due to COX-1 inhibitor and interestingly in 3 patients reaction was evoked by celecoxib which is perceived to be safe alternative for patients with NSAIDs hypersensitivity. Chronic urticaria, asthma and systematic drug intake occurs the main risk factors of hypersensitivity. <h3>Conclusions</h3> Drug hypersensitivity reactions are reported very frequently in population of patients with chronic musculoskeletal disorders. Our studies suggest that patients taking protractedly NSAIDs are in group with high risk of drug hypersensitivity development. <h3>Disclosure of Interest</h3> None declared
SAT0605 Local progesterone injection: new option for management of carpal tunnel syndrome
Authors: SA Raeissadat, L Sedighipour, S Shahraeeni
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> A number of studies, have demonstrated the neuroprotective effects of progesterone and its influence on the recovery after neural injury. Few studies investigated the efficacy of local progesterone in Carpal Tunnel Syndrome. <h3>Objectives</h3> The objective of this study was to compare the long term effects of progesterone versus corticosteroid local injections in patients with mild and moderate carpal tunnel syndrome. <h3>Methods</h3> In this randomized clinical trial, 78 hands with Carpal Tunnel Syndrome were assigned to two groups. Patients were treated with a single local injection of triamcinolone acetonide in one group and single local injection of hydroxy progesterone in the other group. Variables including pain (based on Visual Analogue Scale), symptom severity and functional status (based on Bostone/Levine symptom severity and functional status scale) and nerve conduction study were evaluated before and 6 months after the treatments. <h3>Results</h3> All outcome measures including pain, functional scales and electrophysiologic findings improved in both corticosteroid and progesterone groups and there were no meaningful differences between two groups regarding mentioned variables. However, functional outcome was significantly better in progesterone compared to corticosteroid group at 6 month follow up (P=0.04). <h3>Conclusions</h3> This study demonstrated the efficacy of progesterone local injection in mild and moderate CTS at long term follow up. Furthermore, local progesterone can be superior to corticosteroid injection for relieving symptoms and improving functional and electrophysiologic findings at long term follow up. <h3>Disclosure of Interest</h3> None declared
Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma
Authors: Naoyuki Okabe, Hironori Takagi, Hayato Mine, Satoshi Fukai, Hiroyuki Minemura, Hiroyuki Suzuki
Journal: Journal of Thoracic Oncology (2017)
The Rate of Turnover of the Lecithins and Cephalins of Carcinosarcoma 256 as Measured by Radioactive Phosphorus&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;
Authors: Haven, Frances L.
Journal: JNCI Journal of the National Cancer Institute (1940)

Journal Article The Rate of Turnover of the Lecithins and Cephalins of Carcinosarcoma 256 as Measured by Radioactive Phosphorus Get access Frances L. Haven Frances L. Haven fellow, associate National Cancer Institute, National Institute of Health, United States Public Health Service, and University of Rochester Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 1, Issue 2, October 1940, Pages 205–209, https://doi.org/10.1093/jnci/1.2.205 Published: 01 October 1940
AB1223-HPR Beliefs and attitudes of italian nurses towards placebo and nocebo responses induced by contextual factors in clinical practice
Authors: M Testa, G Rossettini, T Geri, A Viceconti, L Colloca, A Palese
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Placebo and nocebo represent psycho-neuro-immuno-endocrinological responses commonly encountered in nursing care (1,2). A new paradigm proposed the contextual factors (CF) as mediators and moderators of these responses (3). To date, the knowledge about the awareness of CF and their use in nursing is scant. <h3>Objectives</h3> The goal of this study was to examine frequency of use, beliefs and attitudes of Italian specialised nurses regarding the contextual factors. <h3>Methods</h3> In December 2016, through SurveyMonkey Software®, an online survey was conducted by sending a questionnaire to the members of four Italian Nursing Association, grouping nurses specialized in Neuroscience, Medical, Geriatric and Diabetic care. Behaviours, beliefs and attitudes of nurses about the implementation of CF in clinical practice were assessed by a 17 items questionnaire and resulting data were analysed by descriptive statistic. <h3>Results</h3> Of the 1411 members of the involved Nursing Associations invited to participate to the survey 425 responded (30.1%). An high number of respondent nurses adopts CF often in their practice (42%). They believe that CF can positively influence acute pain (47.5%), chronic pain (61%) and rheumatologic disorders (42%). 34% of responders consider the use of CF, if it can determine beneficial psychological effects, as ethically accep table. 15.5% responders oppose to the adoption of CF when based on deception or if they undermines trust between nurses and patients. A relevant number of nurses (24%) do not communicate the use of CF to their patients and 19% implement CF as addition to other nursing interventions to optimize clinical responses. Nurses explain the power of CF through patient9s expectation and psychological mechanism (11%). <h3>Conclusions</h3> The Italian specialised nurses use CF quite frequently and believe that their use has the capacity of positively influencing the clinical outcome. Larger surveys are needed to understand the proportion of use of CF by nurses in common clinical practice in Italy. <h3>References</h3> Miller LR, Miller FG. Understanding placebo effects: Implications for nursing practice. Nurs Outlook. 2015 Sep-Oct;63(5):601–6. Häuser W, Hansen E, Enck P. Nocebo phenomena in medicine: their relevance in everyday clinical practice. Dtsch Arztebl Int. 2012 Jun;109(26):459–65. Palese A, Rossettini G, Testa M. Placebo and nocebo responses in nursing practice: a discussion paper on the role of contextual factors. In revision at Nurs Inq. <h3>Disclosure of Interest</h3> None declared
Neither genotyping nor contact tracing allow correct understanding of multidrug-resistant tuberculosis transmission
Authors: Arthur Fournier, Christine Bernard, Wladimir Sougakoff, Sylvie Quelet, Fadi Antoun, Cécile Charlois-Ou, Isabelle Dormant, Marie-Odile Dufour, Nora Hocine, Vincent Jarlier, Nicolas Veziris
Journal: European Respiratory Journal (2017)

The control of tuberculosis (TB) is challenged by the progressive increase of cases of multi-drug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). A recent European study underlined the need for data showing how TB control can be improved in terms of case finding, contact tracing, infection control and treatment to prevent further spread of MDR-/XDR-TB in the EU [1]. Even combined contact tracing and genotyping fail to explain how MDR-TB transmission occurs in one third of cases <http://ow.ly/2ZKB30dRVGw> Author contributions: N. Veziris is the guarantor of the paper. A. Fournier, F. Antoun and N. Veziris designed the study, gathered data and wrote the manuscript. C. Bernard, W. Sougakoff and C. Charlois-Ou gathered data and corrected the manuscript. S. Quelet and V. Jarlier corrected the manuscript. I. Dormant, M-O. Dufour and N. Hocine gathered data.
SP0084 Biological targets in sle
Authors: C Chizzolini
Journal: Annals of the Rheumatic Diseases (2017)

SLE is a prototypical condition characterized by the complete subversion of immunological tolerance and the generation of autoantibodies directed against a wide array of ubiquitous and tissue-specific antigens. This is possible because the joint dysregulation of the innate and adaptive arms of the immune system; which results from multiple gene polymorphisms, each contributing marginally, distinct epigenetic regulation, alteration of the threshold of activation for T and B cells, enhanced responses of antigen-presenting cells resulting from the altered disposal of apoptotic cells, as well as dysregulation of cytokine circuitries including regulatory networks. Pathogenic mechanisms resulting in clinically overt SLE very likely are heterogeneous among individuals. Thus, the identification of biological targets in SLE goes also with the identification of selected modules of gene activation in distinct individuals. Very strong signals indicate that type I interferon (IFN) may contribute to autoimmunity in a large proportion of SLE individuals and therapeutic trials targeting IFN signaling suggest the clinical relevance of this mediator. B cells/plasmablasts are also relevant and obvious targets. Refinements in our understanding in B cell sub setting and/or the timing in disease development in which they play a relevant role should result in defining the appropriate targets specific to this cell lineage. Gene modules activated during flares suggest that neutrophils in a subset of individuals may also be relevant targets. Cytokine affecting T cell differentiation, in particular T follicular helper cells, represent additional relevant targets. Within the last several years a number of novel biological targets have been identified in SLE. However, a single biological agent has been approved for SLE treatment in the last five decades. This underlies the difficulties encountered when translating validated targets in efficacious therapeutic agents. This stress the need for careful preclinical evaluation. It further emphasizes the need of small phase II clinical trials based on stringent inclusion criteria aiming at precisely identifying individual groups more likely to respond to validate the target. Current progress made in the identification of molecular signatures in individuals with SLE will offer the tools for the requested accurate selection. <h3>Disclosure of Interest</h3> C. Chizzolini Grant/research support from: Unrestricted reserach grant form GSK
Response to Comment on Lewis et al. Management of Hemoglobin Variants Detected Incidentally in HbA1c Testing: A Common Problem Currently Lacking a Standard Approach. Diabetes Care 2017;40:e8–e9
Authors: Michael R. Lewis, Patricia R. Sheehan, Myrlene A. Staten, Lawrence S. Phillips, Anastassios G. Pittas
Journal: Diabetes Care (2017)

We thank Drs. Little and Rohlfing for their comments (1) regarding our article on the management of incidental detection of hemoglobin (Hb) variants in HbA1c testing (2). We agree that awareness of the potential for interference to affect HbA1c results is essential in research and clinical care. Multiple studies (including that of Lin et al. [3]) prior to the 2016 article by Rohlfing et al. (4) had yielded no evidence of clinically significant bias resulting from HbAS or HbAC variants in Tosoh G8 results. In the Vitamin D and Type 2 Diabetes (D2d) Study, we excluded potential participants with HbAE and HbAD because clinically significant bias had been demonstrated.

In a recent article by Rohlfing et al. (4), HbA1c testing using a Tosoh G8 with software version 5.20 was found to show …
SAT0129 Exploration of comorbidity indices in an ethnic rheumatoid arthritis subset
Authors: S Dowell, G Kerr, C Swearingen, M Quinones, J Berrian, S Hochberg
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Comorbidity is common in ethnic patients with rheumatoid arthritis (RA) and often impact choice of DMARD therapy and clinical outcomes. In addition to simple summation of comorbidities, composite indices have been proffered as better predictors of poor clinical outcomes in patients with rheumatoid arthritis<sup>1</sup>. However, their applicability in ethnic RA subsets is unknown. <h3>Objectives</h3> To compare composite to mean comorbidity indices in ethnic subsets with rheumatoid arthritis. <h3>Methods</h3> Patients enrolled in the Ethnic Minority RA Consortium (EMRAC), with at least 6 months of followup data were analyzed. At enrollment, sociodemographic data and RA disease status, rheumatic disease comorbidity index (RCDI)<sup>1</sup> and comorbidity count (COUNT)<sup>1</sup> were analyzed amongst ethnic subsets. Spearman correlation was estimated between RCDI and COUNT while Poisson regression was used to model the differences in the comorbidity indices between race groups. <h3>Results</h3> 453 EMRAC subjects were analyzed; 342 (81.4%) were female, average age was 58.9 (± 15.1) years, average duration 13.3 (±11.1) years and average follow-up length 2.1 (±1.4) years. Individual comorbid frequencies as well as comorbid indices are summarized in Table 1. Spearman correlation between overall RDCI and COUNT was 0.90 (95% CI [0.88, 0.91], P&lt;0.001). Hispanics, however, had significantly lower comorbidity indices scores than other race groups (RDCI Hispanic vs White P=0.003, Hispanic vs Black P=0.004, Hispanic vs Other P=0.038; COUNT Hispanic vs White P=0.012, Hispanic vs Black P=0.004, Hispanic vs Other P=0.151). <h3>Conclusions</h3> In an ethnic RA subset, the RCDI and COUNT correlated well across ethnic groups. The comorbidity indices were not associated with RA disease activity at enrollment as assessed by the RAPID3. Hispanics had lower RCDI and COUNT scores compared to other race groups but also presented at a younger age which could account for this difference. More studies are needed to determine the predictive value of these indices in determining poor outcomes and mortality in this ethnic subset. <h3>References</h3> England, BR et al. Arthritis Care Res. 2015 Jun; 67(6): 885–872. <h3>Disclosure of Interest</h3> S. Dowell Grant/research support from: Bristol Myers Squibb, Pfizer, Genentech, Speakers bureau: Horizon Pharma, G. Kerr Grant/research support from: Bristol Myers Squibb, Pfizer, Genentech, C. Swearingen Grant/research support from: Bristol Myers Squibb, Pfizer, Genentech, M. Quinones Grant/research support from: Bristol Myers Squibb, Pfizer, Genentech, J. Berrian Grant/research support from: Bristol Myers Squibb, Pfizer, Genentech, S. Hochberg Grant/research support from: Bristol Myers Squibb, Pfizer, Genentech